Background: At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients.
introduction
Ewing sarcoma (EWS) is the second most common tumor of bone and soft tissue. It occurs mainly in children and young adults and is characterized by a very aggressive nature with rapid growth and a marked tendency to form distant metastases [1] . Treatment of EWS is based on a combined approach of local therapy with surgery and/or radiotherapy of the primary tumor and systemic chemotherapy based on doxorubicin, vincristine, actinomycin D, ifosfamide and etoposide [2] . Intensified chemotherapy regimens with high doses have been used in patients with poor response to standard chemotherapy leading to some improvements [3] . However, prolonged and intensive chemotherapy treatments are characterized by toxicity and long-term adverse effects [4] . Moreover, cost-effectiveness of treatments is another important problem for EWS patients [4] , where cure mainly relies on public investments. These two aspects render extremely important identification of reliable indicators of prognosis, which may allow stratification of patients according to different risks at diagnosis. At present, only clinico-pathological features, such as presence of clinically evident metastases at diagnosis and poor response to neoadjuvant chemotherapy are widely accepted as prognostic and predictive factors in EWS [4] . In fact, despite many biological and molecular markers have been proposed in past years [5, 6] , their clinical value still needs validation and experimental explanation.
We recently reported that high levels of miR-34a expression in this tumor were associated with a more favorable clinical history likely due to better responses to chemotherapy [7] . In order to further assess its prognostic significance, miR-34a expression was analyzed in a larger series of 109 primary localized tumors *Correspondence to: Dr Katia Scotlandi, CRS Development of Biomolecular Therapies, Experimental Oncology Lab, Rizzoli Institute, via di Barbiano 1/10, 40136 Bologna, Italy. Tel: +39-051-6366760; Fax: +39-051-6366761/763; Email: katia.scotlandi@ior.it from patients treated at a single institution from 1991 to 2009 and in 17 metastases. Analysis of some validated targets of miR34a (cyclin D1, bcl-2, SIRT1 and YY1) was also carried out.
materials and methods

patient selection
Patients with localized EWS who were enrolled in prospective studies and treated at the Rizzoli Institute were included in the present analysis.
The ethical committee of the Rizzoli Institute approved the studies, and informed consent was obtained. Details about patients' selection are provided in supplementary Material and Methods, available at Annals of Oncology online.
sample processing and total RNA isolation Total RNA from tumor samples was isolated from snap-frozen tissue material using Trizol LS Reagent (Invitrogen, Carlsbad, CA). RNA quality and quantity were assessed by NanoDrop analysis (NanoDrop ND1000 ThermoFisher Scientific, Waltham, MA) and/or by electrophoresis analysis (1% agarose gel). To check whether extracted RNA was representative of EWS cells, the tissue was morphologically analyzed after hematoxylin-eosin staining (supplementary Figure S1 , available at Annals of Oncology online) before any processing and patients with nonrepresentative samples (33/142) were excluded.
real time PCR
qRT-PCR analysis of miR-34a was carried out using TaqMan® MicroRNA Assays and TaqMan® Universal PCR Master Mix, no AmpErase® UNG (Applied Biosystems, Foster City, CA, USA) according to manufacturer's instructions. Primer sequences are available in supplementary In keeping with its oncosuppressor role [8] , miR-34a expression was found to be generally lower in EWS with respect to several normal controls, including human bone-marrow-, corion-or dental pulp-derived mesenchymal stem cells, osteoblast precursors as well as muscle and skin (supplementary Figure S2 , available at Annals of Oncology online). Human mesenchymal stem cell (hMSC) primary culture hMSC163 was used as representative ( Figure 1A ): only a minority of patients (15/109, 14%) had miR-34a expression levels remarkably higher (fold change >2) than the normal control, while the others showed comparable or definitely lower levels. To establish clinical relevance of miR-34a expression in EWS, the median was used as cutoff value to stratify patients and define two categories of high or low expressors, as previously reported [7] . Median follow-up of the 109 EWS patients was 67 months (range 9-241 months). Sixtyeight patients (62%) remained continuously free of disease and 41 (38%) relapsed. First relapse pattern consisted of metastases in 35 cases (lungs 17 cases, bones 8, lungs and bones 10), local recurrence in 5, local recurrence and bone metastasis in 1. The clinico-pathological characteristics are reported in Table 1 . Figure 1B ) confirmed that miR-34a expression in localized tumors is associated with a significantly different risk of recurrence: 5-year event-free survival (EFS) was 74% for the 55 patients with high expression of miR-34a [95% confidence interval (CI) 62-82] while it was 51% for the 54 patients with low expression (95% CI 37-64) (P = 0.0071); 5-year overall survival (OVS) was 83% in high expressors (95% CI 73-93) but it was 58% in low expressors (95% CI 44-71) (P = 0.0027).
Considering the predictive significance of tumor response to induction chemotherapy, data were analyzed focusing on this topic. miR-34a expression was similar in good and poor responders (data not shown). In good responder patients, the probability of EFS and OVS were slightly better in case of high miR-34a [5-year EFS: high miR-34a 86% (95% CI 70-100), how miR-34a 71% (95% CI 50-93), 5-year OVS: high miR-34a 90% (95% CI 77-100), low miR-34a 77% (95% CI 57-97)], without statistical differences (5-year EFS: P = 0.2, 5-year OVS: P = 0.2). In poor responder patients, the probability of EFS and OVS again were better in case of high-miR-34a [5-year EFS: high miR-34a 67% (95% CI 45-84), low miR-34a 45% (95% CI 27-64), 5-year OVS: high miR-34a 90% (95% CI 66-96), low miR-34a 54% (95% CI 35-73)], and the difference reached statistical significance (5-year EFS: P = 0.09, 5-year OVS: P = 0.05) in spite of the relatively low number of patients.
To verify the reliability of this type of analysis, we also evaluated whether the impact of miR-34a expression may vary by changing the type of calibrator that was used to define the levels of miR-34a expression. Despite the relative expression of miR34a in individual EWS patients differed when various normal cells or tissues were used as calibrators (Figure 2A ) (statistical variability across the controls for expression of miR-34a was: −ΔC T median = −2.740, standard deviation = 0.882), patients defined with high expression of miR-34a according to the different median values (supplementary Table S2 , available at Annals of Oncology online) always maintained a significantly lower probability to face adverse events. Representative Kaplan-Meier survival curves obtained by using corion-derived hMSCs as calibrator are shown in Figure 2B .
Low miR-34a expression, poor response of tumors after neoadjuvant chemotherapy and high LDH values, which resulted significantly associated with worse clinical outcome in univariate analysis (Table 1) , were all confirmed as independent risk factors associated with poor outcome by multivariate Cox's proportional hazards regression analysis (Table 2 ). Fisher's exact test analysis confirmed that miR-34a expression did not correlate with any of the clinico-pathological characteristics of EWS patients at study entry (supplementary Table S3 , available at Annals of Oncology online).
expression of miR-34a in Ewing sarcoma metastases
RNAs from 5 bone and 12 lung metastases were available and used for miR-34a analysis. miR-34a expression was significantly lower in metastases compared with primary tumors (supplementary Figure S3 , available at Annals of Oncology online) (P = 0.022, Mann-Whitney U-test).
expression of miR-34a correlates with proliferation rate of EWS samples
To further validate the clinical relevance of miR-34a, we also analyzed by qRT-PCR the expression of some genes that were reported to be targeted by miR-34a [9, 10] , including the evaluation of (i) cyclin D1, a cell cycle regulator [11] , (ii) bcl-2, a major antiapoptotic driver [12] , (iii) the transcription factor Yin Yang 1 (YY1), which controls several divergent cellular processes, including cell proliferation and apoptosis [13] and promotes p53 degradation [13] , (iv) SIRT1, a NAD-dependent deacetylase that deactivates p53 [14, 15] . Statistically significant inverse correlations (supplementary Table S4 , available at Annals of Oncology online) were observed between miR-34a levels and expression of cyclin D1 (r = −0.242, P = 0.0114, Spearman's test), bcl-2 (r = −0.182, P = 0.0589) and YY1 (r = −0.200, P = 0.0369), which indeed appeared as molecular hubs of the putative complex network of genes regulated by miR-34a (supplementary Figure S4 , available at Annals of Oncology online, GeneGo network analysis). However, at protein level, when cyclin D1, bcl-2 and YY1 were evaluated on TMA created with matching tumor samples (58 cases), the expression of miR-34a was found to maintain statistically significant inverse correlation only with cyclin D1 expression (r = −0.27, P < 0.05, Pearson's correlation test, supplementary Table S5 , available at Annals of Oncology online). Accordingly, miR-34a expression was evaluated in paired samples and found to inversely correlate with Ki-67 staining (r = −0.31, P = 0.02, Pearson's correlation test).
discussion
A large number of studies have demonstrated that altered expression of specific miRNAs plays an important role in human tumorigenesis [16] . Detection of aberrant miRNA expression levels either in tumors or more recently in blood could be used for prediction of prognosis because miRNAs are stable, resistant to several harsh conditions, and can be detected easily and cheaply by reliable and quantitative methods. Our previous miRNA array data in EWS tissue samples have indicated the possible prognostic relevance of miR-34a. High expression of miR-34a at diagnosis was found to be associated with better outcome [7] . Although interesting, this first evidence warrants further examination in larger cohorts in order to obtain a more general acknowledgement from pathologists and oncologists of the clinical value of miR-34a. Validation of experimental results is always a difficult task in rare tumors. Combination of samples from different institutions may have significant drawbacks in terms of local treatments and/or sample preservation. In contrast, analysis of larger series from single institutions implicates analysis of samples from different decades.
In this study, we analyzed the expression of miR-34a in a retrospective series of 109 tumors, strictly controlled either in terms of clinical or technical parameters and fitting the standards for reporting prognostic biomarkers (REMARK guidelines) [17] . In line with its role as a master driver of tumor suppression, miR-34a expression was found to be generally downregulated in EWS compared with normal tissue or mesenchymal stem cells, which very likely represent the cell of origin of EWS [18] . Expression of miR-34a was lower in metastases compared with primary tumors. In addition, when miR-34a levels were evaluated at diagnosis in localized tumors, they were associated with a significantly different outcome: higher levels correlated with a lower risk to develop secondary events. This evidence was confirmed also when different types of normal calibrators were considered. This is an important point because it indicates that, despite the quantification of miR-34a obtained by quantitative PCR is relative, the use of different normal samples do not alter net results: patients with a higher expression of miRNA have a more favorable outcome. For perspective studies, the use of digital, which provides absolute rather than relative quantification of nucleic acids PCR [19] , may be useful to solve the problem of the definition of a threshold level for miR-34a.
MiR-34a can antagonize many different oncogenic processes by regulating genes that function in various cellular pathways [20] . A major function of miR-34a is the control of cellular proliferation: ectopic expression of miR-34a in cancer cells decreases cell doubling times and leads to G1/G2 arrest. Accordingly, transcripts validated for their interactions with miR-34a include cyclin D1 and E2 as well as cyclin-dependent kinases 4 and 6, all genes involved in promoting cell cycle. Moreover, miR-34a is also involved in regulation of apoptosis: it is transcriptionally induced by p53 and is an important effector in the execution of p53 signaling because it represses Bcl-2, SIRT1 and YY1. Although the ability of miR-34a to impact these cellular processes may suggest that it can act in synergism with conventional cytotoxic therapies, as previously confirmed in experimental conditions in various tumors including EWS [7] , no relation was found between miR-34a expression and pathological response of the primary tumor to induction chemotherapy in our series of patients. The expression of miR34a better discriminate prognosis in patients with poor rather than good responses to chemotherapy. Considering that these patients were treated with high-dose chemotherapy, high miR34a expression very likely characterizes patients whose tumors have a lower biological aggressiveness, in particular a lower propensity to metastasize rather than a higher chemosensitivity. In our samples, it appears that miR-34a function in cell cycle and proliferation is prevalent with respect to apoptosis control. Significant correlations with cyclin D1 and with Ki-67 staining were indeed observed both at mRNA and protein level. At clinical level, the relevance of miR-34a may thus be complemented by Ki-67 expression, which was previously shown to constitute a valuable indicator of poor prognosis in localized EWS [21] . At biological level, however, these evidences may highlight a more complex relationship, which deserves further investigations. Cyclin D1 is expressed at much higher levels in EWS when compared with cancers devoid of EWS fusions and bonemarrow mesenchymal stem cells from which Ewing tumors are thought to originate [22] . EWS-FLI1, the genetic hallmark of EWS, is known to affect transcription and alternative processing of cyclin D1 transcripts, both of which favor EWS cell transformation [22] . Besides its well-defined role in regulating cell cycle, cyclin D1 is indeed involved in several other crucial processes, including induction of cellular migration and invasion, enhancement of angiogenesis, inhibition of mitochondrial metabolism, enhancement of DNA damage sensing and DNA damage repair [11] . Our data showed a correlation between miR-34a and cyclin D1 expression. We can speculate that miR34a may counteract the action of EWS-FLI1 by reducing the expression of a critical driver of EWS transformation also in presence of the oncogene. In addition, cyclin D1 has been recently found to induce expression of Dicer, a central regulator of miRNA maturation [23] , and thereby promotes maturation of miRNA [23] . This new evidence indicates the existence of a complex crosstalk between cyclin D1 and expression of the noncoding genome. Likely, when expression of miR-34a is higher in EWS tumors, cyclin D1 could not evade negative feedback from the noncoding genome and its expression is reduced.
Hence, although we acknowledge the limits that may be related to a retrospective although well-controlled study, we consider that miR-34a constitutes a valuable indicator of good prognosis in localized EWS and strongly recommend its detection in a prospective series of patients. Upregulation of miR-34a in tumors that do not express it could be of great therapeutic interest. Nanotechnology-based approaches and in particular stable nucleic acid lipid particles, which are characterized by good transfection efficiency and stability in serum, have been recently proposed as effective agents to deliver miR-34a in vivo [24] , thus representing a promising tool for miRNA-therapeutics against tumors. 
